AFT Pharmaceuticals : FY22 Results Appendix 2

Results for announcement to the market

	AFT Pharmaceuticals Limited
	Reporting Period	12 months to 31 March 2022
	Previous Reporting Period	12 months to 31 March 2021
	Currency	NZ$
		Amount (000s)			Percentage change
	Revenue from continuing	$130,314			Up 15%
	operations
	Total Revenue	$130,314			Up 15%
	Net profit/(loss) from continuing	$19,848			Up 155%
	operations
	Total net profit/(loss)	$19,848			Up 155%
	Interim/Final Dividend
	Quoted Equity Securities:
	Amount per Quoted Equity	No dividends have been paid on ordinary shares and it is
	Security	currently not proposed to pay dividends.
	Imputed amount per Quoted	Not Applicable
	Equity Security
	Record Date	Not Applicable
	Dividend Payment Date	Not Applicable
		Current period		Prior comparable period
	Net tangible assets per Quoted	$0.18			$0.04
	Equity Security
	A brief explanation of any of the	Accompanying this announcement are the Group's audited
	figures above necessary to	consolidated financial statements for the twelve months
	enable the figures to be	ended 31 March 2022. These financial statements and the
	understood	full year results commentary dated 23 May 2022 provide the
		balance of information requirements in accordance with NZX
		Listing Rule 3.5 and Appendix 2.
		Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals
		Limited confirms that it continues to comply with the rules of
		its home exchange (NZX Main Board).
	Authority for this announcement
	Name of person authorised to	Malcolm Tubby
	make this announcement
	Contact person for this	Malcolm Tubby, Chief Financial Officer,
	announcement	AFT Pharmaceuticals Ltd
	Contact phone number	[phone]
	Contact email address	[e-mail]

Date of release through MAP	23 May 2022

Audited financial statements accompany this announcement.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland0622, New Zealand

Incorporated in New Zealand ARBN: ARBN 609 017 969